Drug intelligence / Profile preview

TQ-A3326

Development stage: Phase 1
Lead developer: Suzhou Southeast Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

TQ-A3326 is a small molecule antiviral drug developed as a deuterated analog of daclatasvir, specifically designed to inhibit the hepatitis C virus (HCV) NS5A protein. By modifying daclatasvir with deuterium, TQ-A3326 aims to improve pharmacokinetic properties and metabolic stability. The drug has been evaluated in healthy volunteers for its pharmacokinetics, metabolism, and tolerability. Fecal excretion is the predominant route of elimination for TQ-A3326 and its metabolites. Its primary indication is for the treatment of hepatitis C virus infection.

Targets

NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))

Beyond the preview

Go deeper on TQ-A3326.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQ-A3326.

Explore the full profile